Candel Therapeutics, Inc. (CADL) Institutional Ownership

Ownership Summary

Recent 13F filings as of September 2025 show that 81 institutional investors hold a position in Candel Therapeutics, Inc. (NASDAQ:CADL).

• The percentage of Candel Therapeutics owned by institutions changed from 46.3% in June 2025 to 41.5% in September 2025, marking a slight down trend.
• The company experienced a -0.19% quarterly change in institutional shares held, alongside an increase of 55.77% in total owners annually.
• The latest 13F cycle for Candel Therapeutics reveals that of 81 total investors, 39 funds grew their exposure, whereas 28 reduced theirs and 14 made no changes.
• The aggregate institutional position in Candel Therapeutics now stands at 22.76Mn shares as of September 2025, after investors decreased their holdings (down by 43.08K shares quarter on quarter which is up 16.03Mn shares year over year).
• With 8.23Mn shares, FMR LLC commands the largest institutional position in Candel Therapeutics as of September 30, 2025, equating to 15.00% of the company.
• Among the most significant buyers of Candel Therapeutics during September 2025 were CITADEL ADVISORS LLC (242.66K), VANGUARD GROUP INC (219.56K), Nuveen, LLC (117.18K), BlackRock, Inc. (77.48K), Lido Advisors, LLC (60.20K).
• Leading sellers of Candel Therapeutics stock in September 2025 included Portolan Capital Management, LLC (237.59K), TWO SIGMA INVESTMENTS, LP (233.08K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (129.48K), Halter Ferguson Financial Inc. (78.51K), MILLENNIUM MANAGEMENT LLC (71.94K).
• The top 10 institutional holders of Candel Therapeutics for the quarter ending September 2025 included FMR LLC (8.23Mn), ACORN CAPITAL ADVISORS, LLC (2.58Mn), BlackRock, Inc. (2.38Mn), VANGUARD GROUP INC (2.01Mn), Portolan Capital Management, LLC (1.38Mn), GEODE CAPITAL MANAGEMENT, LLC (928.20K), Halter Ferguson Financial Inc. (698.00K), STATE STREET CORP (688.77K), Sands Capital Alternatives, LLC (405.84K), NORTHERN TRUST CORP (306.77K).